Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Splenic Marginal Zone Lymphoma (SMZL) is a well-defined low-grade B-cell lymphoma,considered
as a rare neoplasm accounting for about 2% of all non-Hodgkin's lymphomas (NHL) and
represents for most cases of otherwise unclassifiable chronic lymphoid B-cell cluster of
differentiation antigen 5 (CD5)-lymphoproliferative disorders. SMZL is characterized by an
almost exclusive involvement of the spleen and bone marrow and in about 25% of cases the
disease pursues an aggressive course and most patients die of lymphoma progression within 3-4
years.
Retrospective studies have indicated that purine analogous achieved very high response rates
in both naïve and pre-treated patients. Moreover, the introduction of the anti-cluster of
differentiation antigen 20 (CD20) humanized antibody rituximab, either used alone or in
combination with chemotherapy has been reported to be very effective in producing a rapid
clearance of neoplastic cells.
Phase:
Phase 2
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)